Science
Mechanism of Action
This oligopeptide acts by binding to specific epidermal growth factor receptors (EGFR) on skin cell surfaces. This interaction activates intracellular signaling pathways, driving cell proliferation, differentiation, and tissue repair. The cascade of effects aims to rejuvenate skin, bolster its natural barrier, and improve overall texture by stimulating collagen and elastin production. It also supports scarless wound healing, mitigates inflammatory responses, and boosts extracellular matrix components like hyaluronic acid, contributing to long-term moisturization.
Research
Clinical Evidence
Low confidenceN/A
Key findings
- 01 Clinical assessments reported statistically significant improvements in fine lines, skin texture, pore size, and various dyschromatic conditions within one month of use with Oligopeptide-1-containing products.
- 02 A cream formulated with 0.001% sh-oligopeptide-1 demonstrated no added benefit in reducing post-laser edema or hyperpigmentation when compared to a control in a specific clinical trial.
- 03 An EGF-containing cream, often associated with sh-oligopeptide-1, significantly increased skin moisture and elasticity, alongside a reduction in transepidermal water loss (TEWL) after a single week of application.
- 04 Concerns have been raised regarding the scientific basis of many sh-oligopeptide-1 clinical studies, noting potential use of inactive ingredients and lack of adherence to medical standards, questioning if it functions as a true EGF.
Transparency
Dusting Analysis
Given the explicit critiques regarding the scientific validity and potential inactivity of sh-oligopeptide-1 as a functional EGF, and the broad claims without consistent, concentration-dependent efficacy, it presents characteristics of an ingredient prone to 'dusting' in formulations, where its inclusion is more for marketing appeal than proven performance.
The Formula
Formulation
Stability
This ingredient is notably sensitive to pH, requiring the formulation's pH to be carefully adjusted between 5.0 and 8.0 prior to its incorporation. Furthermore, it is susceptible to degradation by microbial enzymes, making rigorous control of microbial contamination during manufacturing crucial for maintaining stability and efficacy.
Safety
Safety Profile
While R-MUSSEL OLIGOPEPTIDE-1 (sh-Oligopeptide-1) is not on EWG's restricted lists and was included in IECIC 2015 as a skin-conditioning agent, significant safety concerns exist. Active EGF is classified as a potent, unauthorized drug and not a cosmetic; sh-oligopeptide-1 is not approved for medical treatments. Although authorized for cosmetic use at various concentrations, its long-term risks remain unknown. A major concern is the potential for tumorigenesis with any growth factor-mimetic ingredients, as EGF signaling pathways are frequently implicated in tumor cell activity, raising cautions for its use in personal care applications.
Your Skin
Skin Compatibility
Our Assessment
Verdict
Despite claims of broad skin benefits and its inclusion in cosmetic formulations, the ingredient faces substantial scientific scrutiny regarding its true efficacy, functional equivalence to EGF, and poses potential long-term safety risks, including concerns about tumorigenesis, thus warranting significant caution in its application.
Related
Similar Ingredients
Finding similar ingredients…
References
Sources